The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—Kymriah (Novartis; Basel, Switzerland) and Yescarta—(Gilead; Foster City, CA) were approved in 2017, and remain one of the hottest immunotherapies on the market today. They work by...
HBO shines light on novel immunotherapies HBO’s Vice news program selected a few promising technologies from the immunotherapy pipeline to feature in its Killing Cancer episode. Vice’s heartrending human interest stories illustrated the potential of three...
About Biotech Primer
From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.
